TABLE 3

Clinical and biochemical characteristics of the case-control cohort

Nondiabetic control subjects
Diabetic patients
All−866G/G−866G/A−866A/APAll−866G/G−866G/A−866A/AP
n (M/F)235/33097/150110/15626/24241/242107/115104/9330/34
Age (years)53 ± 1253 ± 1252 ± 1254 ± 100.6962 ± 10*62 ± 1163 ± 1062 ± 110.53
Age at diagnosis (years)52 ± 1052 ± 1051 ± 1052 ± 100.46
BMI (kg/m2)29.8 ± 6.429.8 ± 6.230.1 ± 6.928.8 ± 4.20.4330.1 ± 6.030.0 ± 5.729.9 ± 5.831.0 ± 7.30.41
Fasting glucose (mg/dl)92 ± 1192 ± 1292 ± 1192 ± 80.78163 ± 73*158 ± 68169 ± 76161 ± 830.35
HbA1c (%)7.5 ± 2.47.5 ± 2.67.5 ± 2.37.6 ± 2.40.94
Total cholesterol (mg/dl)208 ± 43209 ± 46208 ± 41199 ± 340.28207 ± 44210 ± 44203 ± 47208 ± 390.27
HDL cholesterol (mg/dl)52 ± 1452 ± 1352 ± 1451 ± 120.7645 ± 14*45 ± 1346 ± 1646 ± 130.79
Triglycerides (mg/dl)132 ± 71133 ± 76134 ± 70115 ± 530.18165 ± 99*163 ± 93172 ± 110152 ± 890.38
  • Data are means ± SD. Differences between the whole cohort of nondiabetic control subjects and diabetic patients were compared using unpaired Student’s t test. Genotype differences of continuous variables were compared using ANOVA. Categorical variables were compared by χ2 test.

  • *

    * P < 0.0001 vs. nondiabetic control subjects.